Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research, will showcase scientific expertise and its new look at Booth 1736 at the American Association of Cancer Research (AACR) 2016 Annual Meeting April 16-20 in New Orleans.CrownBio will present data on its latest scientific developments including the establishment of new in vivo models with reconstituted human immunity (MiXeno(TM) and a new human PD-L1 expressing model) to test the efficacy of human biologic agents; and models with fully functional murine immunity (syngeneics, MuPrime(R)) to evaluate pharmacodynamics and combination approaches; as well as a HuTrial(TM) case study and the establishment of a panel of pancreatic PDX models, among others.
The authors of 10 CrownBio scientific posters will be presenting their data from 1 to 5 p.m. April 17 (poster 747); from 8 a.m. to 12 p.m. April 19 (poster 3219); from 1 p.m. to 5 p.m. April 19 (posters 3994, 4043); and from 8 a.m. to 12 p.m. April 20 (posters 5176, 5177, 5179, 5184, 5185, 5186).
“We are excited to share our scientific expertise at AACR,” said Henry Li, Ph.D., vice president of translational oncology at CrownBio. “We believe the research our scientists are doing demonstrates our deep commitment to global cancer research as well as our role as a leading provider of preclinical oncology solutions.”
CrownBio will also unveil its new logo, branding and tagline at AACR. To discuss current and upcoming oncology research projects with CrownBio’s experts and see CrownBio’s new look, stop by Booth 1736 or schedule a meeting in advance.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.